Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» RegeneRx Enrolls First Subject In RGN-352 Phase IB Clinical Trial, Reducing Cardiac Damage In Patients After An AMI
RegeneRx Enrolls First Subject In RGN-352 Phase IB Clinical Trial, Reducing Cardiac Damage In Patients After An AMI
RegeneRx Enrolls First Subject In RGN-352 Phase IB Clinical Trial, Reducing Cardiac Damage In Patients After An AMI
Submitted by
admin
on September 23, 2008 - 12:28pm
Source:
Medical News Today
Headline:
RegeneRx Enrolls First Subject In RGN-352 Phase IB Clinical Trial, Reducing Cardiac Damage In Patients After An AMI
Do Not Allow Advertisers to Use My Personal information
